Prognostic significance of Erythropoietin in pancreatic adenocarcinoma

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Welsch, Thilo ^a   Zschäbitz, Stefanie ^a   Becker, Verena ^b,d   Giese, Thomas ^a   Bergmann, Frank ^a   Hinz, Ulf ^a   Keleg, Shereen ^a   Heller, Anette ^a   Sipos, Bence ^c   Klingmüller, Ursula ^b   Büchler, Markus W ^a   Werner, Jens ^a   Giese, Nathalia A ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; PROTEIN KINASE B; AUTOANTIBODY; MESSENGER RNA; PRIMER DNA;

ADULT; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHRONIC PANCREATITIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PANCREAS ADENOCARCINOMA; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK FACTOR; SIGNAL TRANSDUCTION; FLOW CYTOMETRY; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOPRECIPITATION; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; AGED; AUTOANTIBODIES; BASE SEQUENCE; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; DNA PRIMERS; ERYTHROPOIETIN; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ERYTHROPOIETIN; RNA, MESSENGER;

EID: 79960955797     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023151     Document Type: Article

References (52)

1. Nowrousian MR, (1997) Pathophysiology of anemia in cancer. In: Nowrousian MR, editors. Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology: Scientific and Clinical Aspects of Anemia in Cancer Wien NewYork Springer pp. 149-188.
2. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL, (1990) Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322: 1689-1692.
3. Barosi G, (1994) Inadequate erythropoietin response to anemia: definition and clinical relevance. Ann Hematol 68: 215-223.
4. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, et al. (2010) American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 28: 4996-5010.
5. Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, et al. (2002) Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95: 888-895.
6. Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H, (1994) Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 73: 2535-2542.
7. Aapro MS, Link H, (2008) September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 13 (Suppl 3): 33-36.
8. Juneja V, Keegan P, Gootenberg JE, Rothmann MD, Shen YL, et al. (2008) Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer. Clin Cancer Res 14: 3242-3247.
9. Aapro M, Scherhag A, Burger HU, (2008) Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients. Br J Cancer 99: 14-22.
10. Henke M, Laszig R, Rube C, Schafer U, Haase KD, et al. (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362: 1255-1260.
11. Szenajch J, Wcislo G, Jeong JY, Szczylik C, Feldman L, (2010) The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells From clinic to bench- a critical review. Biochim Biophys Acta 1806: 82-95.
12. Pajonk F, Weil A, Sommer A, Suwinski R, Henke M, (2004) The erythropoietin-receptor pathway modulates survival of cancer cells. Oncogene 23: 8987-8991.
13. Ribatti D, Marzullo A, Gentile A, Longo V, Nico B, et al. (2007) Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma. Histopathology 50: 591-596.
14. Arcasoy MO, (2008) Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives. Clin Cancer Res 14: 4685-4690.
15. Papworth K, Bergh A, Grankvist K, Ljungberg B, Rasmuson T, (2009) Expression of erythropoietin and its receptor in human renal cell carcinoma. Tumour Biol 30: 86-92.
16. Inthal A, Krapf G, Beck D, Joas R, Kauer MO, et al. (2008) Role of the erythropoietin receptor in ETV6/RUNX1-positive acute lymphoblastic leukemia. Clin Cancer Res 14: 7196-7204.
17. Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, et al. (1993) JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 74: 227-236.
18. Klingmuller U, (1997) The role of tyrosine phosphorylation in proliferation and maturation of erythroid progenitor cells-signals emanating from the erythropoietin receptor. Eur J Biochem 249: 637-647.
19. Richmond TD, Chohan M, Barber DL, (2005) Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol 15: 146-155.
20. Becker V, Schilling M, Bachmann J, Baumann U, Raue A, et al. (2010) Covering a broad dynamic range: information processing at the erythropoietin receptor. Science 328: 1404-1408.
21. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, et al. (2001) Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61: 3561-3565.
22. Mirmohammadsadegh A, Marini A, Gustrau A, Delia D, Nambiar S, et al. (2010) Role of erythropoietin receptor expression in malignant melanoma. J Invest Dermatol 130: 201-210.
23. Sinclair AM, Rogers N, Busse L, Archibeque I, Brown W, et al. (2008) Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. Br J Cancer 98: 1059-1067.
24. Arcasoy MO, Jiang X, Haroon ZA, (2003) Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun 307: 999-1007.
25. Ribatti D, Marzullo A, Longo V, Poliani L, (2007) Schwann cells in neuroblastoma express erythropoietin. J Neurooncol 82: 327-328.
26. Elliott S, Busse L, Bass MB, Lu H, Sarosi I, et al. (2006) Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 107: 1892-1895.
27. Laugsch M, Metzen E, Svensson T, Depping R, Jelkmann W, (2008) Lack of functional erythropoietin receptors of cancer cell lines. Int J Cancer 122: 1005-1011.
28. Glimelius B, Linne T, Hoffman K, Larsson L, Svensson JH, et al. (1998) Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer. J Clin Oncol 16: 434-440.
29. Dernedde U, Dernedde R, Shepstone L, Barrett A, (2007) Three-year single institution audit on transfusion requirements in oncology patients. Clin Oncol (R Coll Radiol) 19: 223-227.
30. Welsch T, Degrate L, Zschabitz S, Hofer S, Werner J, et al. (2011) The need for extended intensive care after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Langenbecks Arch Surg 396: 353-362.
31. Beguin Y, Clemons GK, Pootrakul P, Fillet G, (1993) Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 81: 1067-1076.
32. Roque ME, Sandoval MJ, Aggio MC, (2001) Serum erythropoietin and its relation with soluble transferrin receptor in patients with different types of anaemia in a locally defined reference population. Clin Lab Haematol 23: 291-295.
33. Opasich C, Cazzola M, Scelsi L, De Feo S, Bosimini E, et al. (2005) Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 26: 2232-2237.
34. van der Meer P, Voors AA, Lipsic E, Smilde TD, van Gilst WH, et al. (2004) Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 44: 63-67.
35. Bartel M, Hansch GM, Giese T, Penzel R, Ceyhan G, et al. (2008) Abnormal crosstalk between pancreatic acini and macrophages during the clearance of apoptotic cells in chronic pancreatitis. J Pathol 215: 195-203.
36. Welsch T, Keleg S, Bergmann F, Degrate L, Bauer S, et al. (2009) Comparative analysis of tumorbiology and CD133 positivity in primary and recurrent pancreatic ductal adenocarcinoma. Clin Exp Metastasis 26: 701-711.
37. Samyn I, Fontaine C, Van Tussenbroek F, Pipeleers-Marichal M, De Greve J, (2004) Paraneoplastic syndromes in cancer: Case 1. Polycythemia as a result of ectopic erythropoietin production in metastatic pancreatic carcinoid tumor. J Clin Oncol 22: 2240-2242.
38. Ketteler R, Heinrich AC, Offe JK, Becker V, Cohen J, et al. (2002) A functional green fluorescent protein-erythropoietin receptor despite physical separation of JAK2 binding site and tyrosine residues. J Biol Chem 277: 26547-26552.
39. Westphal G, Braun K, Debus J, (2002) Detection and quantification of the soluble form of the human erythropoietin receptor (sEpoR) in the growth medium of tumor cell lines and in the plasma of blood samples. Clin Exp Med 2: 45-52.
40. Hardee ME, Rabbani ZN, Arcasoy MO, Kirkpatrick JP, Vujaskovic Z, et al. (2006) Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Mol Cancer Ther 5: 356-361.
41. Yin D, Kawabata H, Tcherniamtchouk O, Huynh T, Black KL, et al. (2007) Glioblastoma multiforme cells: expression of erythropoietin receptor and response to erythropoietin. Int J Oncol 31: 1193-1198.
42. Dunlop EA, Maxwell AP, Lappin TR, (2007) Impaired downregulation following erythropoietin receptor activation in non-small cell lung carcinoma. Stem Cells 25: 380-384.
43. Rades D, Setter C, Dahl O, Schild SE, Noack F, (2010) Prognostic Impact of Erythropoietin Expression and Erythropoietin Receptor Expression on Locoregional Control and Survival of Patients Irradiated for Stage II/III Non-Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys.
44. Acs G, Xu X, Chu C, Acs P, Verma A, (2004) Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer 100: 2376-2386.
45. Zeh HJ, Winikoff S, Landsittel DP, Gorelik E, Marrangoni AM, et al. (2005) Multianalyte profiling of serum cytokines for detection of pancreatic cancer. Cancer Biomark 1: 259-269.
46. Martignoni ME, Kunze P, Hildebrandt W, Kunzli B, Berberat P, et al. (2005) Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin Cancer Res 11: 5802-5808.
47. Poch B, Lotspeich E, Ramadani M, Gansauge S, Beger HG, et al. (2007) Systemic immune dysfunction in pancreatic cancer patients. Langenbecks Arch Surg 392: 353-358.
48. Ramadori P, Ahmad G, Ramadori G, (2010) Cellular and molecular mechanisms regulating the hepatic erythropoietin expression during acute-phase response: a role for IL-6. Lab Invest 90: 1306-1324.
49. Minamishima YA, Kaelin WG Jr, (2010) Reactivation of hepatic EPO synthesis in mice after PHD loss. Science 329: 407.
50. Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowska H, Kulig A, et al. (2009) Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig Dis Sci 54: 683-689.
51. Phillips TM, Kim K, Vlashi E, McBride WH, Pajonk F, (2007) Effects of recombinant erythropoietin on breast cancer-initiating cells. Neoplasia 9: 1122-1129.
52. Cao Y, Lathia JD, Eyler CE, Wu Q, Li Z, et al. (2010) Erythropoietin Receptor Signaling Through STAT3 Is Required For Glioma Stem Cell Maintenance. Genes Cancer 1: 50-61.